- CITATIONS: 2
|Application ||WB, IHC-P, IF, E|
|Other Accession||P20171, Q61411|
|Calculated MW||21298 Da|
|Antigen Region||104-128 aa|
|Other Names||GTPase HRas, H-Ras-1, Ha-Ras, Transforming protein p21, c-H-ras, p21ras, GTPase HRas, N-terminally processed, HRAS, HRAS1|
|Target/Specificity||This HRAS antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 104-128 amino acids from the Central region of human HRAS.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||HRAS Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.|
|Cellular Location||Cell membrane. Cell membrane; Lipid-anchor; Cytoplasmic side. Golgi apparatus. Golgi apparatus membrane; Lipid-anchor. Note=The active GTP-bound form is localized most strongly to membranes than the inactive GDP-bound form (By similarity). Shuttles between the plasma membrane and the Golgi apparatus.|
|Tissue Location||Widely expressed.|
Provided below are standard protocols that you may find useful for product applications.
HRAS belongs to the Ras oncogene family, whose members are related to the transforming genes of mammalian sarcoma retroviruses. These proteins function in signal transduction pathways. They can bind GTP and GDP, and they have intrinsic GTPase activity. HRAS undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus. Mutations in this gene cause Costello syndrome, a disease characterized by increased growth at the prenatal stage, growth deficiency at the postnatal stage, predisposition to tumor formation, mental retardation, skin and musculoskeletal abnormalities, distinctive facial appearance and cardiovascular abnormalities. Defects in the HRAS gene are implicated in a variety of cancers, including bladder cancer, follicular thyroid cancer, and oral squamous cell carcinoma.
Winter-Vann,A.M., Proc. Natl. Acad. Sci. U.S.A. 100 (11), 6529-6534 (2003)
Coats,S.G., Biochemistry 38 (39), 12926-12934 (1999)
Sakai,E., Int. J. Cancer 52 (6), 867-872 (1992)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.